The Retinal Vascular Occlusion drugs in development market research report provides comprehensive information on the therapeutics under development for Retinal Vascular Occlusion, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Retinal Vascular Occlusion. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Retinal Vascular Occlusion and features dormant and discontinued products.

GlobalData tracks 38 drugs in development for Retinal Vascular Occlusion by 33 companies/universities/institutes. The top development phase for Retinal Vascular Occlusion is preclinical with 20 drugs in that stage. The Retinal Vascular Occlusion pipeline has 38 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Retinal Vascular Occlusion pipeline products market are: ANBITION, AffaMed Therapeutics US and Avirmax.

The key targets in the Retinal Vascular Occlusion pipeline products market include Vascular Endothelial Growth Factor A (Vascular Permeability Factor or VEGFA), Vascular Endothelial Growth Factor (VEGF) , and Vascular Endothelial Growth Factor Receptor 2 (Fetal Liver Kinase 1 or Kinase Insert Domain Receptor or Protein Tyrosine Kinase Receptor flk 1 or VEGFR2 or CD309 or KDR or EC

The key mechanisms of action in the Retinal Vascular Occlusion pipeline product include Vascular Endothelial Growth Factor A (Vascular Permeability Factor or VEGFA) Inhibitor with eight drugs in Pre-Registration. The Retinal Vascular Occlusion pipeline products include seven routes of administration with the top ROA being Intravitreal and seven key molecule types in the Retinal Vascular Occlusion pipeline products market including Small Molecule, and Monoclonal Antibody.

Retinal Vascular Occlusion overview

Retinal vascular occlusion is a condition that affects the blood vessels in the retina, the light-sensitive layer of tissue at the back of the eye. It occurs when a blood vessel is blocked by a clot or compressed by another vessel, preventing blood from reaching or leaving the retina. This can cause vision loss or blindness in the affected eye. There are two main types of retinal vascular occlusion: retinal artery occlusion and retinal vein occlusion. Both types can have serious complications, such as swelling, bleeding, or abnormal blood vessel growth in the eye. Retinal vascular occlusion is more common in middle-aged and older people, and in people with risk factors such as atherosclerosis, high blood pressure, diabetes, or blood clotting disorders. The diagnosis is based on a comprehensive eye exam and tests such as a fundus photography, fluorescein angiography, or optical coherence tomography. The treatment depends on the type and severity of the occlusion, and may include medication injections, laser therapy, or surgery. The goal of treatment is to prevent or reduce vision loss and complications.

For a complete picture of Retinal Vascular Occlusion’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.